Oncotarget

Research Papers:

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival

Karen Klepsland Mauland _, Elisabeth Wik, Erling A. Hoivik, Kanthida Kusonmano, Mari Kyllesø Halle, Anna Berg, Hans Kristian Haugland, Anne Margrete Øyan, Karl-Henning Kalland, Ingunn Marie Stefansson, Lars A. Akslen, Camilla Krakstad, Jone Trovik, Henrica Maria Johanna Werner, Helga Birgitte Salvesen

PDF |  HTML  |  Supplementary Files  |  Author Information  |  Order a Reprint

Oncotarget. 2017; 8:9696-9707. doi: 10.18632/oncotarget.14201

Metrics: PDF 150 views  |   HTML 148 views  |   ?  


Abstract

Karen Klepsland Mauland1,2, Elisabeth Wik3,4,*, Erling A. Hoivik1,2,*, Kanthida Kusonmano2,5,6, Mari Kyllesø Halle1,2, Anna Berg1,2, Hans Kristian Haugland4, Anne Margrete Øyan1,7, Karl-Henning Kalland1,7, Ingunn Marie Stefansson4, Lars A. Akslen3,4, Camilla Krakstad1,8, Jone Trovik1,2, Henrica Maria Johanna Werner1,2, Helga Birgitte Salvesen1,2,**

1Center for Cancer Biomarkers CCBIO, Department of Clinical Science (K2), University of Bergen, Bergen, Norway

2Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway

3Center for Cancer Biomarkers CCBIO, Department of Clinical Medicine (K1), Section for Pathology, University of Bergen, Bergen, Norway

4Department of Pathology, Haukeland University Hospital, Bergen, Norway

5Computational Biology Unit, University of Bergen, Bergen, Norway

6Bioinformatics and Systems Biology Program, School of Bioresources and Technology, King Mongkut’s University of Technology Thonburi, Bangkhuntien, Bangkok, Thailand

7Department of Microbiology, Haukeland University Hospital, Bergen, Norway

8Center for Cancer Biomarkers CCBIO, Department of Biomedicine, University of Bergen, Bergen, Norway

*These authors have contributed equally to this work

**Deceased

Correspondence to:

Karen Klepsland Mauland, email: Karen.Mauland@uib.no

Keywords: endometrial cancer, DNA ploidy, prognosis, transcriptional alterations, chromosome 15q

Received: October 06, 2016     Accepted: November 23, 2016     Published:

ABSTRACT

Aneuploidy is a widely studied prognostic marker in endometrial cancer (EC), however, not implemented in clinical decision-making. It lacks validation in large prospective patient cohorts adjusted for currently standard applied prognostic markers, including estrogen/progesterone receptor status (ER/PR). Also, little is known about aneuploidy-related transcriptional alterations, relevant for understanding its role in EC biology, and as therapeutic target.

We included 825 EC patients with available ploidy status and comprehensive clinicopathologic characterization to analyze ploidy as a prognostic marker. For 144 patients, gene expression data were available to explore aneuploidy-related transcriptional alterations.

Aneuploidy was associated with high age, FIGO stage and grade, non-endometrioid histology, ER/PR negativity, and poor survival (p-values<0.001). In patients with ER/PR negative tumors, aneuploidy independently predicted poor survival (p=0.03), lymph node metastasis (p=0.007) and recurrence (p=0.002). A prognostic ‘aneuploidy signature’, linked to low expression of chromosome 15q genes, was identified and validated in TCGA data.

In conclusion, aneuploidy adds prognostic information in ER/PR negative EC, identifying high-risk patients that could benefit from more aggressive therapies. The ‘aneuploidy signature’ equally identifies these aggressive tumors and suggests a link between aneuploidy and low expression of 15q genes. Integrated analyses point at various dysregulated pathways in aneuploid EC, underlining a complex biology.

Author Information

Karen Klepsland Mauland
Primary Contact  _

Elisabeth Wik

Erling A. Hoivik

Kanthida Kusonmano

Mari Kyllesø Halle

Anna Berg

Hans Kristian Haugland

Anne Margrete Øyan

Karl-Henning Kalland

Ingunn Marie Stefansson

Lars A. Akslen

Camilla Krakstad

Jone Trovik

Henrica Maria Johanna Werner

Helga Birgitte Salvesen


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14201